반응식
[C:1]1([CH2:7][O:8][C:9]([NH:11][C@H:12]([C:17]([OH:19])=O)[CH2:13][CH:14]([CH3:16])[CH3:15])=[O:10])[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.[NH2:20][C@H:21]([CH2:26][OH:27])[CH2:22][CH2:23][CH2:24][CH3:25]>>[C:1]1([CH2:7][O:8][C:9]([NH:11][C@H:12]([C:17]([NH:20][C@H:21]([CH2:26][OH:27])[CH2:22][CH2:23][CH2:24][CH3:25])=[O:19])[CH2:13][CH:14]([CH3:15])[CH3:16])=[O:10])[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=1참가 물질
3
실험 절차
N-[(phenylmethoxy)carbonyl]-L-leucine was used instead of 1-[[(phenylmethoxy)carbonyl]amino]cyclohexanecarboxylic acid, and L-norleucinol was used instead of L-valinol in the process according to Reference Example 178 to obtain 421 mg (58%) of the title compound.
출처 및 근거
- ORD 기록
- ord-d7d5a8b2750f42bfbf6ced8702089204
- 출처 데이터셋
- uspto-grants-2013_07
- 특허 번호
- US08481725B2
연결된 노트
불러오는 중…